Antinuclear Antibody Test Market Report 2026

The antinuclear antibody test market size has grown rapidly in recent years. It will grow from $1.73 billion in 2025 to $1.95 billion in 2026 at a compound annual growth rate (CAGR) of 12.5%. The growth in the historic period can be attributed to increasing prevalence of autoimmune disorders, expansion of clinical laboratory testing services, growing physician reliance on serological diagnostics, availability of immunofluorescence assay technologies, rising patient diagnostic testing volumes.

The antinuclear antibody test market size is expected to see rapid growth in the next few years. It will grow to $3.09 billion in 2030 at a compound annual growth rate (CAGR) of 12.2%. The growth in the forecast period can be attributed to increasing adoption of ai-assisted diagnostic interpretation, rising demand for point-of-care autoimmune testing, expansion of integrated laboratory information systems, growing focus on personalized autoimmune diagnostics, increasing investments in advanced assay technologies. Major trends in the forecast period include increasing adoption of multiplex and automated ana testing, rising demand for early autoimmune disease screening, growing use of digital pathology and lims integration, expansion of high-throughput diagnostic platforms, enhanced focus on diagnostic accuracy and standardization.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the antinuclear antibody test market in the coming years. Autoimmune diseases are disorders in which the immune system mistakenly attacks the body's own healthy cells and tissues. The rising incidence of autoimmune diseases is attributed to factors such as genetic predisposition, environmental influences, hormonal changes, and lifestyle factors including diet and stress. The antinuclear antibody test aids in the early detection of autoimmune diseases by detecting antibodies that target the body's own cells and tissues. For example, in February 2024, according to Arthritis Australia, an Australia-based charitable not-for-profit organisation supporting individuals with arthritis and musculoskeletal conditions, approximately 562,378 Australians are expected to be living with rheumatoid arthritis (RA) by 2025, representing 14% of the total arthritis population. Consequently, the growing prevalence of autoimmune diseases is fueling the expansion of the antinuclear antibody test market.

The increasing adoption of personalized medicine is anticipated to drive the growth of the antinuclear antibody (ANA) test market in the coming years. Personalized medicine involves tailoring medical treatments and diagnostic decisions according to an individual’s genetic, environmental, and lifestyle characteristics, rather than using a one-size-fits-all approach. The rise of personalized medicine is fueled by the demand for more precise diagnostic tools that facilitate patient stratification, early detection of autoimmune diseases, and therapy monitoring. ANA tests are vital in precision immunology as they detect autoimmune biomarkers that are crucial for guiding targeted treatment strategies. For example, in February 2024, the Personalized Medicine Coalition reported that 26 new personalized therapies were approved by the U.S. FDA in 2023, including 20 new molecular entities and 6 gene- or cell-based treatments. Consequently, the increasing emphasis on personalized medicine is contributing to the expansion of the antinuclear antibody test market.

Major companies operating in the antinuclear antibody (ANA) test market are concentrating on developing advanced solutions, such as semi-automated image analysis, to improve diagnostic accuracy and optimize laboratory workflow. Semi-automated image analysis is a technological feature in ANA testing that captures, organizes, and pre-classifies patient specimens based on fluorescence patterns, helping prioritize cases that need detailed review by a trained operator. For example, in June 2023, Immuno Concepts, a US-based provider of autoimmune diagnostic reagents and instrumentation, introduced the Immuno Concepts IgG Anti-nDNA Fluorescent Test System for use with its Image Navigator semi-automated microscope. It is designed to support laboratory technicians in both qualitative and semi-quantitative detection of anti-double-stranded DNA (dsDNA) IgG antibodies in human serum. The system employs indirect immunofluorescence on a C. luciliae substrate and a fluorescein-conjugated anti-human IgG reagent. The Image Navigator captures images of each specimen, categorizes them into “possible negative” and “possible positive” groups with over 97% accuracy, and presents them for final review, thereby enhancing reproducibility, reducing hands-on time, and ensuring standardized interpretation across laboratories.

Major companies operating in the antinuclear antibody test market are Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Becton Dickinson and Company, LabCorp, Quest Diagnostics Incorporated, Grifols SA, PerkinElmer Inc., Bio-Rad Laboratories Inc., Werfen SA, DiaSorin SpA, EUROIMMUN AG, Abcam plc, Trinity Biotech plc, Zeus Scientific Inc., ERBA Diagnostics Inc., Quidel Corporation, Antibodies Incorporated, Immuno Concepts Inc., Inova Diagnostics.

North America was the largest region in the antinuclear antibody test market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antinuclear antibody test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antinuclear antibody test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the antinuclear antibody test market by increasing costs of imported assay kits, reagents, imaging systems, software platforms, and laboratory automation equipment. Clinical laboratories and hospitals in North America and Europe are most affected due to reliance on imported diagnostic consumables, while Asia-Pacific faces cost pressures on assay kit manufacturing and exports. These tariffs are increasing testing costs and affecting laboratory procurement decisions. However, they are also encouraging domestic production of diagnostic kits, regional reagent manufacturing, and local development of advanced autoimmune testing solutions.

The antinuclear antibody test market research report is one of a series of new reports that provides antinuclear antibody test market statistics, including antinuclear antibody test industry global market size, regional shares, competitors with a antinuclear antibody test market share, detailed antinuclear antibody test market segments, market trends and opportunities, and any further data you may need to thrive in the antinuclear antibody test industry. This antinuclear antibody test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

An antinuclear antibody (ANA) test is a blood test that identifies autoantibodies directed against the body’s own cells, which may indicate autoimmune diseases. It is frequently used to help diagnose conditions such as lupus, rheumatoid arthritis, and other autoimmune disorders.

The primary categories of products in the antinuclear antibody test include assay kits, reagent kits, and software and services. Assay kits are pre-packaged collections of reagents and protocols developed to detect antinuclear antibodies in patient samples. They incorporate a range of technologies, including immunofluorescence assays, multiplex assays, and ELISA, and are applied in the diagnosis of conditions such as rheumatoid arthritis, systemic lupus erythematosus, and others. These products serve various end users, including hospitals, clinical laboratories, and physician laboratories.

The antinuclear antibody test market consists of revenues earned by entities by providing services such as laboratory testing services, specialized testing services, monitoring disease activity, and screening for systemic lupus erythematosus. The market value includes the value of related goods sold by the service provider or included within the service offering. The antinuclear antibody test market also includes sales of diagnostic equipment and instruments, testing kits, western blot kits and luminex multiplex assays. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.